Small molecule
A newer type of Crohn's medicine taken as a tablet that works inside cells to calm inflammation, such as upadacitinib.
Also called: filgotinib, tablet treatment
Related words biologic jak inhibitor upadacitinib
Topics Medicines
A newer type of Crohn's medicine taken as a tablet that works inside cells to calm inflammation, such as upadacitinib.
Also called: filgotinib, tablet treatment
Related words biologic jak inhibitor upadacitinib
Topics Medicines
Crohn's & Colitis UK says iron deficiency anaemia is common in Crohn's, caused by blood loss from the gut, poor absorption or too little iron in the diet. Symptoms include tiredness, breathlessness, headaches and pale skin, says the NHS. Treatment may be iron tablets or iron given into a vein; a Cochrane review found iron through a drip probably helps more people than tablets.
Sources
Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.
Sources
Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.
Topics Medicines Immunosuppressants Research
Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response
NICE's appraisal recommending upadacitinib (Rinvoq), a tablet, for adults with moderate to severe Crohn's disease after a biologic has not worked, stopped working or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Medicines Biologics and newer medicines
Jargon explained JAK inhibitor small molecule TNF-alpha inhibitor
A guide to upadacitinib (Rinvoq), a tablet that belongs to the JAK inhibitor group of targeted medicines. It explains how blocking JAK proteins calms the immune response, what trials showed, and the side effects and safety checks involved.
Topics Medicines Biologics and newer medicines
Jargon explained JAK inhibitor Janus kinase targeted medicine small molecule
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)
Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE
A Spanish multi-centre study of 94 people with Crohn's and low B12, many after ileal surgery. Most who took B12 by mouth reached normal levels, suggesting tablets may be an option for some instead of injections. Treatment choices should be made with your own team.
Topics Anaemia Diet and nutrition Research
Jargon explained vitamin b12 deficiency cyanocobalamin ileal resection
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics Biologics and newer medicines Medicines
Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics Biologics and newer medicines Research
Jargon explained head-to-head trial biologic-naive confidence interval
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics Biologics and newer medicines Medicines
Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics Biologics and newer medicines Research
Jargon explained network meta-analysis relative risk number needed to treat biosimilar